Medtronic plc

Overview

Medtronic plc is a global healthcare technology company founded in 1949 and headquartered in Dublin, Ireland, serving healthcare systems, physicians, clinicians, and patients in more than 150 countries. Its mission is “to alleviate pain, restore health, and extend life,” reflecting a long-standing focus on applying biomedical engineering to medical care.[1][2]

The company’s business is centered on device-based medical therapies and services, organized into four main areas: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Across these segments, Medtronic’s portfolio includes products such as cardiac rhythm devices including pacemakers, insulin pumps, surgical technologies, and patient monitoring systems, which help define its position within the medtech sector.[3]+4

Medtronic operates at global scale, with more than 95,000 employees across more than 150 countries. In fiscal 2025, it generated net sales of $33.537 billion, with $17.171 billion from the United States and the balance largely from international markets, underscoring a broad geographic footprint alongside a substantial U.S. presence.[8][9] [1]+8

Products & services

Medtronic’s product portfolio includes implantable cardiac rhythm devices such as Azure MRI SureScan pacemakers, which use BlueSync wireless connectivity for automatic remote monitoring, and the Micra leadless transcatheter pacing systems, which eliminate the subcutaneous device pocket and include Micra VR and Micra AV models for atrioventricular block.[10] In defibrillation and monitoring, it sells Cobalt and Crome implantable cardioverter defibrillators and cardiac resynchronization devices, Reveal LINQ and LINQ II insertable cardiac monitors with remote programming, and TYRX antibacterial envelopes.[11]+2 Its electrophysiology and structural-heart products include PulseSelect, Arctic Front, DiamondTemp, Sphere-9 and Affera cardiac ablation systems, the CoreValve and Evolut TAVR family for transcatheter aortic valve replacement, Harmony and Melody transcatheter pulmonary valves, and vascular devices such as Resolute Onyx and Onyx Frontier drug-eluting stents, IN.PACT drug-coated balloons, the Symplicity Spyral renal denervation system, Abre venous stents, HawkOne atherectomy and ClosureFast and VenaSeal venous therapies.[14]+6 Service offerings embedded in this portfolio include Care Management Services, Cath Lab Managed Services, and remote monitoring services.[21][22]

In neuroscience, Medtronic sells spine surgery, navigation and robotics systems such as StealthStation S8, Stealth Autoguide, O-arm imaging, Mazor X robotics, and UNiD surgical planning, as well as spinal implants and biologics including CATALYFT PL, Solera Voyager, ZEVO, Prestige LP and Infuse Bone Graft.[23]+4 Its neurovascular range includes Pipeline Flex and Pipeline Vantage flow-diversion devices, Solitaire revascularization devices, Riptide aspiration systems, Onyx liquid embolics and React catheters for aneurysm and stroke treatment.[28] Neuromodulation products include Intellis, Vanta and Inceptiv spinal cord stimulators, Percept PC and Percept RC deep brain stimulation systems with BrainSense capability, SenSight directional leads, SynchroMed III drug infusion pumps, and InterStim X, InterStim II and rechargeable InterStim Micro sacral neuromodulation systems.[29]+3

In medical surgical and diabetes, Medtronic offers surgical stapling and energy products including Tri-Staple, Endo GIA, Signia, LigaSure and Sonicision; the Hugo robotic-assisted surgery system for soft-tissue procedures; and Touch Surgery Enterprise, an AI-enabled surgical video and analytics platform used for training and workflow support.[33]+2 Its endoscopy and GI products include GI Genius intelligent endoscopy, PillCam capsule endoscopy, Bravo reflux monitoring, EndoFLIP, Emprint ablation, Barrx and Nexpowder, while acute-care products include Nellcor monitoring, BIS and INVOS brain and tissue monitoring, Microstream capnography, McGRATH MAC laryngoscopy and Shiley airway tubes.[36]+5 In diabetes, key products include the MiniMed 780G insulin pump system with SmartGuard automation, smartphone and Bluetooth connectivity, meal-detection capability and an adjustable glucose target down to 100 mg/dL, along with Guardian Connect continuous glucose monitoring and the InPen Bluetooth-enabled smart insulin pen.[5]+2 By reported segment, Cardiovascular represented about 37% of FY2025 net sales, Neuroscience 29%, Medical Surgical 25%, and Diabetes 8%.[43] [10]+35

Geographic presence

Medtronic plc lists its principal executive offices at Building Two, Parkmore Business Park West, Galway, Ireland, and the company describes itself as headquartered in Galway with a presence across more than 150 countries. It also identifies an operational headquarters in Minneapolis, Minnesota, and says it has more than 95,000 employees in 350 locations worldwide.[44]+2

In fiscal 2025, Medtronic reported total net sales of $33.537 billion, with $17.171 billion in the U.S. and $16.365 billion internationally, a roughly 51%/49% split. On a customer-location basis, Ireland accounted for $116 million of net sales, the United States for $17.171 billion, and the rest of the world for $16.250 billion.[46]+2

Starting in fiscal 2025, Medtronic combined its former non-U.S. developed markets and emerging markets into a single international geography and recast prior periods to match. Under the prior FY2024 presentation, Medtronic reported $16.562 billion of sales in the U.S., $9.979 billion in non-U.S. developed markets, and $5.823 billion in emerging markets; the company defined non-U.S. developed markets as Japan, Australia, New Zealand, Korea, Canada, and Western Europe, while emerging markets included the Middle East, Africa, Latin America, Eastern Europe, and Asian countries outside that developed-market group. Operational assets are weighted toward the U.S.: at April 25, 2025, property, plant and equipment, net, was $5.133 billion in the United States, $291 million in Ireland, and $1.414 billion in the rest of the world.[48]+5 [44]+10

Business segments

Medtronic reports four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit [3]. Using FY2025 net sales, Cardiovascular was the largest segment at $12.481 billion, or about 37% of consolidated revenue; Neuroscience contributed $9.846 billion, or about 29%; Medical Surgical contributed $8.407 billion, or about 25%; and Diabetes contributed $2.755 billion, or about 8% [53]. A small remainder sat outside the reportable segments in other operating activities [53].

The Cardiovascular Portfolio is organized around Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular, covering therapies for heart rhythm disorders and heart failure, heart valve and aortic disease, and coronary, peripheral vascular, and venous disease [54]+3. The Neuroscience Portfolio includes Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation, spanning neuro and spine surgery, stroke and ENT therapies, pelvic health, spinal cord stimulation, brain modulation, and implantable drug infusion [58]+3.

The Medical Surgical Portfolio is divided into Surgical & Endoscopy and Acute Care & Monitoring, focused on advanced and general surgery, robotic-assisted surgery, wound closure, hernia and endoscopy products, plus patient monitoring and airway management [61]+2. The Diabetes Operating Unit focuses on products and services for managing Type 1 and Type 2 diabetes, including insulin delivery and glucose monitoring systems [63][64]. [3]+14

Company history

Medtronic was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical electronics repair business. In 1957, it developed its first major product, a battery-operated pacemaker, which became a foundational milestone in the company’s early growth. In 1960, Bakken wrote the Medtronic Mission, which became a longstanding statement of the company’s purpose and values.[65]+2

Over the following decades, Medtronic broadened beyond its original cardiac roots through a series of important acquisitions. The 1999 merger with Sofamor Danek expanded its spine and neurosurgery capabilities, the 2001 acquisition of MiniMed established a major presence in diabetes management, and the 2007 acquisition of Kyphon further strengthened its spine portfolio. A major structural turning point came in 2015, when Medtronic completed its acquisition of Covidien and combined the businesses under Medtronic plc, incorporated in Ireland.[68]+4 [65]+7

Sources

• Medtronic plc — Full financial report (2024 Y)
  50 citations

  [1][4][5][6][7][10][11][12][13][14][15][16][17][18][19][20][22][23][24][25][26][27][28][29][30][31][32][33][34][36][37][38][39][40][41][42][49][50][51][52][54][55][56][57][58][59][60][61][62][63]
• Medtronic plc — Full financial report (2025 Y)
  12 citations

  [2][3][9][21][35][43][44][46][47][48][53][64]
• Medtronic plc — Press release (2025 Y)[8]
• www.medtronic.com[45]
• news.medtronic.com[65]
• www.medtronic.com[66]
• www.medtronic.com[67]
• www.medtronic.com[68]
• www.meddeviceonline.com[69]
• www.sec.gov[70]
• www.sec.gov[71]
• www.globenewswire.com[72]